MedTrace Logo

ApTOLL for the Treatment of COVID-19

NCT05293236 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-08-07

No results posted yet for this study

Summary

There is a clear and urgent medical need of developing new medicinal products for COVID-19 since there are poor pharmacological tools to block the progression of patients to cytokine storm syndrome (CSS). To this aim, this Phase Ib clinical study (APTACOVID) pretends to determine whether ApTOLL, in combination with the standard of care, is safe and shows any biological effect) in those patients infected with SARS-CoV-2 who are not developed CSS yet.

Conditions

Interventions

DRUG

ApTOLL

ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)

OTHER

Saline

Saline for intravenous infusion

Sponsors & Collaborators

  • Centro para el Desarrollo Tecnológico Industrial

    collaborator UNKNOWN

  • Macarena Hernández Jiménez

    lead INDUSTRY

Principal Investigators

  • Macarena Hernández, PhD · aptaTargets S.L.

  • Sergio Serrano, MD · Hospital Universitario Ramón y Cajal

  • Ignacio Santos, MD · Hospital Universitario La Princesa

  • Marc Ribó, MD, PhD · aptaTargets S.L.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-14
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05293236 on ClinicalTrials.gov